News Coverage 10.28.20 Share on Twitter Share on Facebook Share on LinkedIn Blood Test Could Predict the Best Type of Treatment for Metastatic Melanoma A new study finds that people with lower levels of tumor DNA in their blood stream may be better candidates for immune checkpoint inhibitors as a first treatment. Determining Treatment for Metastatic Melanoma A blood test or “liquid biopsy” can pick up bits of tumor DNA in your bloodstream. Lower levels of circulating tumor DNA could mean you’ll have a better response to immune checkpoint inhibitors for metastatic melanoma. Use of liquid biopsy is increasing across all phases of cancer screening, diagnosis and treatment. Related Announcement PICI Hosts 2024 Spring Scientific Retreat Press Release BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes Announcement, From Bench to Fireside Episode Nine: Katie Campbell, PhD
Press Release BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes